...
首页> 外文期刊>International journal of immunopathology and pharmacology. >SACCHAROMYCES CEREVISIAE FUNGEMIA, A POSSIBLE CONSEQUENCE OF THE TREATMENT OF CLOSTRIDIUM DIFFICILE COLITIS WITH A PROBIOTICUM
【24h】

SACCHAROMYCES CEREVISIAE FUNGEMIA, A POSSIBLE CONSEQUENCE OF THE TREATMENT OF CLOSTRIDIUM DIFFICILE COLITIS WITH A PROBIOTICUM

机译:糖酵母酿酒酵母,用益生菌处理艰难梭菌结肠炎的可能后果

获取原文
获取原文并翻译 | 示例
           

摘要

The yeast Saccharomyces boulardii is a biotherapeutic agent used for the prevention and treatment of several gastrointestinal diseases, such as diarrhoea caused by Clostridium difficile, in addition to the antibiotic therapy. In this study we report a case of Saccharomyces cerevisiae fungemia in a patient with Clostridium difficile-associated diarrhoea (CDAD) treated orally with S. boulardii in association with vancomycin. The identification of the S. cerevisiae was confirmed by molecular technique. Fungemia is a rare, but a serious complication to treatment with probiotics. We believe it is important to remind the clinicians of this risk when prescribing probiotics, especially to immunocompromised patients.
机译:酵母葡萄球菌是一种生物治疗剂,除抗生素疗法外,还用于预防和治疗几种胃肠道疾病,例如艰难梭菌引起的腹泻。在这项研究中,我们报告了一例经酿酒酵母与万古霉素联合治疗的艰难梭状芽胞杆菌相关性腹泻(CDAD)患者的酿酒酵母真菌病。通过分子技术证实了酿酒酵母的鉴定。真菌病是一种罕见但严重的益生菌治疗并发症。我们认为在处方益生菌时,特别是对免疫功能低下的患者,应提醒临床医生这种风险,这一点很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号